<- Go Home
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Market Cap
$228.4M
Volume
782.3K
Cash and Equivalents
$82.3M
EBITDA
-$15.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$5.8M
Profit Margin
N/A
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
-1.60
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$15.1M
Return on Equity
363.42%
Return on Assets
-13.97
Cash and Short Term Investments
$82.3M
Debt
$60.0M
Equity
-$135.8M
Revenue
N/A
Unlevered FCF
-$8.5M
Sector
Biotechnology
Category
N/A